Eisai Inc., the US pharmaceutical subsidiary of Japan’s Eisai Co. Ltd., has officially moved its US headquarters from Woodcliff Lake to the ON3 complex in Nutley. The move will bring approximately 800 jobs to the region and, at full capacity, the new state-of-the-art facility will accommodate 1,300 employees.
This move to 200 Metro Blvd. provides employees with a dynamic and technologically advanced work environment that reinforces Eisai’s commitment to innovation and the pursuit of its human healthcare mission to provide life-changing therapies and health-related solutions for helping people live healthier and more fulfilling lives.
The Company’s presence in the United States also includes three early-stage discovery research centers, as well as commercial, clinical development and global demand organizations.
“Eisai’s decision to relocate to the ON3 campus is a demonstration of our continued commitment to New Jersey and to being part of this diverse life sciences hub,” said Tatsuyuki Yasuno, President of Eisai Inc. and of the Americas region. “With a 400-seat auditorium and an innovation center in our new US headquarters, we are establishing dedicated space and resources to educate and motivate our employees, as well as a forum to hear from patients, advocacy partners and the community. Through this collaboration, we can have a positive impact on people and society and fulfill our mission of human health care.
“We recently met with the leaders of Eisai and were extremely impressed,” Nutley Mayor Mauro Tucci said. “Eisai is a global pharmaceutical company, committed to human health care, which values the communities in which it operates. We welcome Eisai to Nutley and look forward to working with them to improve our township. We thank them for their investment in our community and the surrounding area.
The ON3 campus straddles Nutley and Clifton.
“New Jersey has established itself as the global epicenter of the biopharmaceutical industry, and we are proud to see an innovative company like Eisai come to Clifton,” said Clifton Mayor James Anzaldi. “Given the urgency of new treatments for cancer and neurological diseases, we look forward to seeing the important work done by Eisai have a positive societal impact and improve the lives of our residents and people around the world.”